Lutein supplementation leads to decreased soluble complement membrane attack complex sC5b‐9 plasma levels. (27th August 2014)

• Record Type: Journal Article
• Authors: Tian, Yuan; Kijlstra, Aize; van der Veen, Rob L. P.; Makridaki, Maria; Murray, Ian J.; Berendschot, Tos T. J. M.
• Is Part Of: Acta ophthalmologica. Volume 93:Number 2(2015)
• Page Start: 141
• Page End: 145
• Publication Date: 2014-08-27
• Subjects: Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1111/aos.12535
• Languages: English
• ISSNs: 1755-375X

Abstract

<abstract abstract-type="main" id="aos12535-abs-0001"> <title>Abstract</title> <sec id="aos12535-sec-0001" sec-type="section"> <title>Purpose</title> <p>The purpose of this study was to investigate the effect of lutein on systemic complement activation in elderly individuals.</p> </sec> <sec id="aos12535-sec-0002" sec-type="section"> <title>Methods</title> <p>Seventy patients with signs of early age‐related macular degeneration (AMD) were included in this study. All subjects were randomly assigned to receive a 10 mg daily dose of lutein or a placebo for a time period of 1 year. EDTA blood was collected before and at various time‐points during the study (0, 4, 8 and 12 months). The plasma level of the soluble complement membrane attack complex sC5b‐9 was measured by ELISA.</p> </sec> <sec id="aos12535-sec-0003" sec-type="section"> <title>Results</title> <p>We found a significant 1.1 ng/ml monthly decrease in the plasma sC5b‐9 concentration in the lutein group (p < 0.001), resulting in a decrease from 60.3 ng/ml at baseline to 46.3 ng/ml at 12 months. For the placebo group, we found a significant 0.6 ng/ml monthly increase in plasma sC5b‐9 concentration (p = 0.001), resulting in an increase from 51.6 ng/ml at baseline to 58.4 ng/ml at 12 months.</p> </sec> <sec id="aos12535-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Lutein supplementation inhibits the systemic activation of the complement system, which provides further functional evidence for the reported beneficial effects of this carotenoid in the management of AMD.</p> </sec> </abstract>